Neurology | Home | MIMS Malaysia

Dimethyl fumarate superior to teriflunomide for preventing relapse in RRMS

Jairia Dela Cruz, 19 hours ago

Dimethyl fumarate appears to prevent relapse more effectively in relapsing-remitting multiple sclerosis (RRMS) compared with teriflunomide, as shown in the results of a real-world study.

Rapid relief of migraine pain with orally dissolving rimegepant

Pearl Toh, Yesterday

A new orally dissolving tablet (ODT) formulation of rimegepant showed rapid onset of action and sustained benefits in terms of pain relief and symptom improvement in patients with acute migraine, the 303 study finds.

Big data promising for optimal triage and management of stroke patients

Dr. Joseph Delano Fule Robles, 2 days ago

A team of statisticians, neurosurgeons and radiologists from the University of Hong Kong (HKU) and the Hospital Authority has designed a stroke algorithm created from big data that will allow optimal triage and management of patients suspected to have large vessel occlusion (LVO) stroke.

Novel 3-drug combo offers hope for Charcot-Marie-Tooth patients

Pearl Toh, 2 days ago

A novel three-drug cocktail, PXT3003, reduces disability in patients with Charcot-Marie-Tooth Type 1A disease (CMT1A) along with a favourable safety profile, according to the PLEO-CMT study presented at AAN 2019, providing hope for a rare disease which so far has no cure.

Hypertension impairs cognitive function in middle-aged adults

Stephen Padilla, 2 days ago

Both prevalent and incident hypertension correlate with poorer global cognitive performance in middle-aged individuals, and this negative effect of hypertension on cognition appears to be true as well in younger patients with a short exposure to high blood pressure (BP), according to a new study.

Virtual reality useful for pain reduction, cognitive rehab and medical training

Christina Lau, 3 days ago

Virtual reality (VR) can be used to reduce pain during wound care for burn patients, facilitate cognitive rehabilitation for patients with neurological or psychiatric disorders, and transform medical training for healthcare staff, according to data presented at the 2019 Hong Kong Hospital Authority Convention.

Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes

04 May 2018

Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.

Management of dementia beyond cognition – a deeper look into BPSD and CVD

13 Dec 2017

At the Schwabe-Menarini lunch symposium of the 11^th International Congress of the Asian Society AgainstDementia (ASAD) 2017 held in Bangkok, Thailand, Professor Ralf Ihl highlighted the role of standardized Gingko biloba extract EGb 761^®for the treatment of patients with behavioural and psychological symptoms of dementia (BPSD). Meanwhile, Associate Professor Nagaendran Kandiah presented clinical findings on the association between cerebrovascular disease (CVD) and dementia, and emphasized the role of EGb 761^®in the management of dementia with CVD.

Drug and non-drug approaches to managing tension-type headache

01 Jul 2017

At the recent launch of Nurofen^® Express by Reckitt Benckiser Malaysia, Ms Joyce McSwan spoke on the importance of managing tension-type headache (TTH), highlighting the roles of drug and non-drug approaches in improving treatment outcomes.

Hypertension and cholesterol lowering interventions do not reduce cognitive decline

Roshini Claire Anthony, 22 Nov 2016

Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.

An uncommon cause of hyperthyroidism

Dr. Rose Zhao-Wei Ting, 16 Nov 2016

A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.

Rapid relief of migraine pain with orally dissolving rimegepant

Pearl Toh, 22 May 2019

Novel 3-drug combo offers hope for Charcot-Marie-Tooth patients

Pearl Toh, 21 May 2019

Eculizumab cuts relapse risk in NMOSD

Pearl Toh, 20 May 2019

The terminal complement inhibitor eculizumab significantly lowered relapse risk in patients with neuromyelitis optical spectrum disorder (NMOSD) who were positive for aquaporin-4 antibodies (AQP4-IgG) compared with placebo, according to the PREVENT* study presented at AAN 2019.

Cannabidiol may halve seizure risk in Dravet syndrome

Roshini Claire Anthony, 16 May 2019

A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).

Isradipine disappoints in Parkinson’s disease

Roshini Claire Anthony, 15 May 2019

Use of the antihypertensive drug isradipine did not reduce the progression of Parkinson’s disease, according to the STEADY-PD III* study presented at the American Academy of Neurology annual meeting (AAN 2019).

Intensive/guideline-directed BP-lowering after ischaemic stroke yield similar functional outcomes

Roshini Claire Anthony, 25 Feb 2019

Among patients with a recent acute ischaemic stroke treated with thrombolytic therapy, intensive blood pressure (BP)-lowering conferred no additional benefit in functional recovery compared with guideline-recommended BP-lowering, despite a reduced risk of intracranial haemorrhage with intensive therapy, according to results of the ENCHANTED* trial.